Search Results
The value of zanubrutinib in the CLL treatment armamentarium & SEQUOIA trial updates
Updated long-term follow-up of SEQUOIA: zanubrutinib vs bendamustine-rituximab in untreated CLL/SLL
SEQUOIA: zanubrutinib-based treatment for CLL with del(17p)
Zanubrutinib plus venetoclax for patients with CLL
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL
Sequoia trial: Which subset of patients with CLL/SLL benefits the most from zanubritinib treatment?
Zanubrutinib improves PFS compared to ibrutinib for R/R CLL and small lymphocytic lymphoma
Safety and efficacy of zanubrutinib in patients with B-cell malignancies
Zanubrutinib in patients with CLL intolerant to ibrutinib and acalabrutinib
Health-related quality of life with zanubrutinib versus ibrutinib for patients with R/R CLL
Selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in CLL
Brukinsa (zanubrutinib) has been approved for CLL/SLL!
